Teva Pharmaceutical Industries Ltd unveiled its financial results for the fourth quarter on Wednesday and provided its adjusted earnings and revenue perspectives for 2024.
The company is currently estimating adjusted earnings for fiscal 2024 to fall between $2.20 and $2.50 per share. This corresponds to revenues projected to land somewhere between $15.7 billion and $16.3 billion.
Analysts consulted by Thomson Reuters anticipate the company to report earnings of $2.42 per share with revenues reaching $15.57 billion for the year. It's worth noting that these estimates usually do not include extraordinary items.
Furthermore, Teva has announced its plan to divest its API business – which encompasses its research and development, manufacturing, and commercial activities – through a sale. The completion of this divestment is expected in the first half of 2025.
